手术性周边虹膜切除术联合房角分离术与房角切开术对比小梁切除术治疗晚期原发性闭角型青光眼:一项随机临床试验
这项在中国8家三级眼科中心开展的非劣效性随机临床试验纳入88例无白内障的晚期原发性闭角型青光眼患者,比较手术性周边虹膜切除术联合房角分离术与房角切开术(SPI+GSL+GT)与小梁切除术。12个月时SPI+GSL+GT组平均眼压15.6 mm Hg vs 小梁切除术组14.9 mm Hg(差值0.5 mm Hg,95%CI -1.2至2.2,P=.55),在4 mm Hg非劣效界值内;完全成功率较低(60.5% vs 82.2%,P=.03),术后干预更少(7.0% vs 55.6%,P<.001)。
要点
- 12个月眼压SPI+GSL+GT组15.6 mm Hg vs 小梁切除术组14.9 mm Hg,差值0.5 mm Hg(95%CI -1.2至2.2),在4 mm Hg非劣效界值内。
- 完全成功率SPI+GSL+GT组60.5% vs 小梁切除术组82.2%(差值-21.8%,95%CI -40.2%至-2.4%,P=.03)。
- 术后干预SPI+GSL+GT组7.0% vs 小梁切除术组55.6%(差值48.6%,95%CI 32.2%至65.0%,P<.001)。
核心结论
- 在无白内障的晚期原发性闭角型青光眼患者中,SPI+GSL+GT在12个月眼压方面不劣于小梁切除术(4 mm Hg界值),术后干预更少但用药无差异。
- 作者认为SPI+GSL+GT可作为类似病例中小梁切除术的潜在替代方案,但需在更大样本量和更小非劣效界值的研究中验证。
研究设计与样本
- 非劣效性随机临床试验,在中国8家三级眼科中心开展,2022年1月至2023年7月纳入88例中国患者(88眼),按1:1随机分为SPI+GSL+GT组43例和小梁切除术组45例,86例(97.7%)完成12个月随访。
- 患者平均(SD)年龄60.3(7.3)岁,52例(59.1%)为女性;数据于2024年8月至2024年9月分析。
主要发现
- 12个月时SPI+GSL+GT组平均(SD)眼压15.6(4.0)mm Hg vs 小梁切除术组14.9(4.2)mm Hg,差值0.5 mm Hg(95%CI -1.2至2.2;P=.55),在4 mm Hg非劣效界值内。
- 合格成功率SPI+GSL+GT组38/43例(88.4%)vs 小梁切除术组42/45例(93.3%),差值-5.0%(95%CI -19.6%至8.5%;P=.48)。
- 完全成功率SPI+GSL+GT组26例(60.5%)vs 小梁切除术组37例(82.2%),差值-21.8%(95%CI -40.2%至-2.4%;P=.03)。
- 术后并发症SPI+GSL+GT组8例(18.6%)vs 小梁切除术组9例(20.0%),差值-1.4%(95%CI -17.9%至15.1%;P=.71)。
- 术后干预SPI+GSL+GT组3例(7.0%)vs 小梁切除术组25例(55.6%),差值48.6%(95%CI 32.2%至65.0%;P<.001);用药中位数(IQR)分别从2(0-3)降至0(0-1)和从2(2-3)降至0(0-0),差值-0.81(95%CI -1.36至-0.26;P=.004)。
关键数值与推荐
- 主要结局为12个月眼压,非劣效界值4 mm Hg。
- 手术成功定义:眼压5-18 mm Hg且较基线下降≥20%,联合或不联合抗青光眼药物。
- 完全成功率SPI+GSL+GT组60.5% vs 小梁切除术组82.2%(差值-21.8%,95%CI -40.2%至-2.4%;P=.03)。
- 合格成功率SPI+GSL+GT组88.4% vs 小梁切除术组93.3%(差值-5.0%,95%CI -19.6%至8.5%;P=.48)。
临床怎么用
- 作者认为,对于无白内障的晚期原发性闭角型青光眼患者,SPI+GSL+GT可作为小梁切除术的潜在替代方案,但需在更大样本量和更小非劣效界值的研究中验证。
局限性
- 作者指出需在更大样本量和更小非劣效界值的研究中验证上述结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The safety and effectiveness of combining surgical peripheral iridectomy (SPI) with goniosynechialysis (GSL) and goniotomy (GT) vs trabeculectomy for intraocular pressure (IOP) reduction remains unknown. OBJECTIVE: To investigate the safety and effectiveness at 1 year of SPI + GSL + GT vs trabeculectomy in advanced primary angle-closure glaucoma (PACG) without cataract. DESIGN, SETTING, AND PARTICIPANTS: This noninferiority randomized clinical trial was conducted at 8 tertiary eye centers in China. A total of 88 Chinese patients (88 eyes) with advanced PACG without cataract were enrolled from January 2022 to July 2023. Data were analyzed from August 2024 to September 2024. Mean (SD) patient age was 60.3 (7.3) years, and 52 patients (59.1%) were female. Forty-three patients were randomized to SPI + GSL + GT and 45 were randomized to trabeculectomy; 86 patients (97.7%) completed the 12-month follow-up. INTERVENTIONS: Participants were randomized 1:1 to receive SPI + GSL + GT or trabeculectomy. MAIN OUTCOMES AND MEASURES: The primary outcome was IOP at 12 months (noninferior margin: 4 mm Hg). Secondary outcomes included surgical success (IOP: 5-18 mm Hg, ≥20% reduction from baseline, with or without antiglaucoma medications); postoperative complications and interventions, including bleb massage, suture lysis, or releasable sutures; and number of antiglaucomatous medications prescribed. RESULTS: At 12 months, the SPI + GSL + GT group had a mean (SD) IOP of 15.6 (4.0) mm Hg vs 14.9 (4.2) mm Hg in the trabeculectomy group (difference, 0.5 mm Hg; 95% CI, -1.2 to 2.2; P = .55), which was within the 4-mm Hg noninferiority margin. Qualified success rates were 38 of 43 participants (88.4%) for SPI + GSL + GT and 42 of 45 participants (93.3%) for trabeculectomy (difference, -5.0%; 95% CI, -19.6% to 8.5%; P = .48). However, complete success rates were lower in the SPI + GSL + GT group (26 participants [60.5%]) vs the trabeculectomy group (37 participants [82.2%]; difference, -21.8%; 95% CI, -40.2% to -2.4%; P = .03). Postoperative complications were present for 8 participants (18.6%) in the SPI + GSL + GT group vs 9 participants (20.0%) in the trabeculectomy group (difference, -1.4%; 95% CI, -17.9% to 15.1%; P = .71). Postoperative interventions were lower in the SPI + GSL + GT group (3 participants [7.0%] vs 25 participants [55.6%]; difference, 48.6%; 95% CI, 32.2%-65.0%; P < .001). Median (IQR) numbers of medications used decreased from 2 (0-3) to 0 (0-1) in the SPI + GSL + GT group and from 2 (2-3) to 0 (0-0) in the trabeculectomy group (difference, -0.81; 95% CI, -1.36 to -0.26; P = .004). CONCLUSIONS AND RELEVANCE: In this randomized clinical trial among patients with advanced PACG without cataract, SPI + GSL + GT demonstrated noninferiority (4-mm Hg margin) to trabeculectomy for IOP at 12 months, with fewer interventions (including bleb massage, suture lysis, or releasable sutures) but no difference in postoperative medication use. This suggests SPI + GSL + GT as a potential alternative to trabeculectomy for similar cases, pending validation in larger sample sizes with smaller noninferiority margins. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05163951.
引用
- Lin F, Lv A, Li F, et al. Peripheral Iridectomy With Goniosynechialysis and Goniotomy vs Trabeculectomy for Advanced PACG: A Randomized Clinical Trial. JAMA Ophthalmol. 2025. PMID: 40244579. doi:10.1001/jamaophthalmol.2025.0757
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。